AMSTERDAM — For patients with diffuse cutaneous systemic sclerosis, an autoimmune disease for which there are few treatment options, lenabasum (JBT-101, Corbus Pharmaceuticals) shows potential, new ...
Opportunities lie in strategic investment formulation, identifying cost-effective locations for conducting trials, understanding global trial trends, and analyzing trial success rates. Insights into ...
Sheffield Teaching Hospitals NHS Foundation Trust has become the only site in the UK to open a groundbreaking international ...
Please provide your email address to receive an email when new articles are posted on . Nearly 10% of patients with systemic sclerosis had systemic sclerosis sine scleroderma, a subtype without skin ...
New research at ACR Convergence 2023, the American College of Rheumatology's (ACR) annual meeting, reports the incidence and risk factors for new-onset interstitial lung disease (ILD) in previously ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback